Skip to content 
AMM 150: MicronJet Revolution with Aesthetic Pain-Free Injections
July 26, 2024
This episode focuses on the latest advancements in aesthetic medicine, highlighting a new device called MicronJet. This intradermal injection device utilizes MEMS technology for precise, pain-free delivery of aesthetic products, making it suitable for delicate areas like around the eyes. Crescita Therapeutics Inc. is preparing to launch this device in Canada in 2025, with strong backing from global clinical studies and regulatory approvals. Tune in to understand how this innovation aims to improve patient outcomes and support clinicians’ practices.
Quick Takes
- MicronJet is an intradermal injection device equipped with three tiny 0.6mm silicon crystal pyramids.
- Crescita Therapeutics Inc. plans to launch MicronJet in Canada in the first half of 2025, pending regulatory approval from Health Canada.
- NanoPass, the company behind MicronJet, is partnering with Crescita to introduce the device to the Canadian market, aiming to enhance patient outcomes and expand clinicians’ practices.
Episode Transcript
Hi everyone, today’s date is July 26, 2024.
Let’s dive into the latest news in aesthetic medicine. There’s a new device making waves, and it’s called MicronJet. This intradermal injection device is built with MEMS technology, making it incredibly effective and virtually pain-free. It’s equipped with three tiny silicon crystal pyramids, each just 0.6mm. MicronJet can be attached to standard syringes, providing precise and minimally invasive delivery of aesthetic products. Whether it’s treating delicate areas around the eyes or the full face, it’s designed for optimal outcomes with minimal discomfort.
Crescita Therapeutics Inc., led by President and CEO Serge Verreault, is keen on expanding their portfolio with this innovative device. They plan to launch MicronJet in Canada in the first half of 2025, pending regulatory approval from Health Canada. MicronJet already boasts global acceptance, backed by over 70 clinical studies and multiple peer-reviewed publications. It’s approved in several regions, including the US, Europe, and Asia.
Daniel Levitats, the CEO of NanoPass—the company behind MicronJet—expressed excitement about partnering with Crescita to introduce this advanced delivery solution to the Canadian market. This collaboration supports Crescita’s strategic vision and aims to enhance patient outcomes while expanding clinicians’ practices.
That’s it for today. Stay tuned for more updates on innovations in aesthetic medicine.
